Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Sciegen Pharmaceuticals Inc
EIR
•Sciegen Pharmaceuticals Inc•June 21, 2019

Sciegen Pharmaceuticals Inc – FDA EIR, Jun 21, 2019

Record Details

An FDA inspection of ScieGen Pharmaceuticals Inc. in Hauppauge, NY, was conducted from June 10 to June 21, 2019. This routine inspection, focusing on Current Good Manufacturing Practices (cGMP) for generic prescription drug manufacturing under the Food Drug and Cosmetic Act, identified three significant observations. The primary issue cited was the company's failure to thoroughly investigate unexplained discrepancies in distributed batches, specifically inadequate Out-of-Specification (OOS) investigations for product assay and dissolution testing. Furthermore, the inspection revealed a lack of comprehensive written procedures for production and process controls, notably concerning blend hold time studies. A third observation highlighted deficiencies in master production and control records, which lacked complete manufacturing and control instructions, including unwritten verification steps in batch records. These issues indicate shortcomings in quality control and documentation processes crucial for ensuring product identity, strength, quality, and purity. At the conclusion of the inspection, a Form FDA 483 detailing these observations was issued to the Chief Operating Officer, Mr. Siva Reddy Palempalli Venkata, who verbally committed to providing a response to the agency within 15 business days, outlining plans for corrective and preventive actions.

Company
Sciegen Pharmaceuticals Inc
Inspection date
June 21, 2019
Product type
drugs
Office
New York District Office
People
  • Jogy George
  • Lata C. Mathew
  • Bala Murali (company_representative)
  • Siva Reddy Palempalli Venkata (recipient)
  • Pailla Malla Reddy (company_representative)
View Company Profile

ID · 4efb8eb0-db23-4e94-a8e6-55482a840592

Violation Codes4
FD&C Act 501(a)(2)(B)21 CFR 211.160(d)21 CFR 211.186(b)21 CFR 211.192

Full citation text and observation details available on the Dashboard.

Other documents for Sciegen Pharmaceuticals Inc
  • 483 - 2023-04-17April 17, 2023
  • 483 - 2022-09-02September 2, 2022
  • 483 - 2021-12-20December 20, 2021
  • EIR - 2018-03-16March 16, 2018
  • 483 - 2015-01-09January 9, 2015

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Sciegen Pharmaceuticals Inc
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.